03.15.19

Nicox Signs Agreement for Zerviate in China for Up to €17 Million in Milestone Payments Plus Royalties

Source: Nicox

Nicox SA and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of allergic conjunctivitis for a territory comprising mainland China, Hong Kong, Macau, and Taiwan. Nicox and Ocumension recently also entered into a collaboration for the development and commercialization of NCX 470 for patients with glaucoma or ocular hypertension, in the same territory. 

Ocumension Therapeutics is an ophthalmology company funded by 6 Dimensions Capital, one of the leading global healthcare investment funds, formed by the merger of Wuxi Healthcare Ventures and Frontline BioVentures.

Ocumension will receive exclusive rights for the agreed territory to develop and commercialize Zerviate. Under the terms of the agreement, Nicox may potentially receive development and sales milestones of up 17 million together with royalties of between 5% and 9% on sales of Zerviate. 

“Following our collaboration on NCX 470, Ocumension was the obvious choice for us to partner with for Zerviate in this region,” Gavin Spencer, Chief Business Officer of Nicox, said in a company news release. “Nicox has built a track record of successful partnerships, and we are actively engaged in discussions to further maximize the value of our commercial and development assets outside of the U.S. and the EU markets.  We look forward to announcing more international collaborations for Zerviate in the coming months.”

“Zerviate brings Ocumension an additional late stage opportunity and expands our therapeutic area coverage into ocular allergy,” said Ye Liu, Chief Executive Officer of Ocumension. “We very much appreciate the collaboration with the Nicox team, and this deal further strengthens our relationship with one of the leading R&D companies in the ophthalmology space.”

Ocumension is expected to have to conduct additional clinical studies for the regulatory approval of Zerviate in the Chinese market. All development activities will be overseen by a Joint Development Committee comprising representatives of both companies, with Ocumension responsible for undertaking all the activities at its own cost.

Related Content